Johnson & Johnson CEDEAR (JNJ)
BCBA
27,800.00
+440.00 (+1.61%)
Closed
Oct 7, 2026
Day's Range
27,680.0028,000.00
52 wk Range
17,010.0029,820.00
Financial Statements - JNJ - Johnson & Johnson CEDEAR
Revenue
94.19B▼ 99.9%
Net Income
26.80B▼ 99.9%Net Margin 28.5%
EBITDA
35.16B▼ 99.9%
Free Cash Flow
19.31B▼ 99.9%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 94.19B | 127.41T | 85.15B | 79.99B | 78.74B | 82.58B |
| Cost of Goods | 30.25B | 39.40T | 26.55B | 24.59B | 23.40B | 28.42B |
| Gross Profit | 63.93B | 88T | 58.60B | 55.39B | 55.33B | 54.15B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 25.59B | 30.48T | 23.40B | 22.21B | 20.94B | 19.73B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 6.89B | -7.38T | -8.80B | -3.05B | -1.63B | -3.14B |
| Pre Tax Income | 32.58B | 23.93T | 15.06B | 19.35B | 19.17B | 16.49B |
| Income Tax | 5.77B | 3.75T | 1.73B | 2.98B | 1.37B | 1.78B |
| Net Income | 26.80B | 20.17T | 35.15B | 17.94B | 20.87B | 14.71B |
| EPS Basic | 2.226302 | 1.168796 | 2.776 | 1.372432 | 1.586114 | 1.117855 |
| EPS Diluted | 2.206 | 1.158 | 2.744 | 1.346 | 1.562 | 1.102 |
| Basic Shares Outstanding | 12.03B | 17.26T | 11.98M | 12.37M | 12.44M | 12.46M |
| Diluted Shares Outstanding | 12.03B | 17.26T | 11.98M | 12.37M | 12.44M | 12.46M |
| Ebit | 33.55B | 25.01T | 15.83B | 19.63B | 19.36B | 16.69B |
| Ebitda | 35.16B | 45.79T | 32.32B | 30.16B | 27.86B | 24.17B |
| Net Income Continuous Operations | 26.80B | 20.17T | 35.15B | 17.94B | 20.87B | 14.71B |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
